Abstract
BackgroundResistance to immune checkpoint inhibitors (ICIs) is a significant barrier to improving cancer immunotherapy.1 To this end, we interrogated ICI-induced inflammation. One type of inflammation, driven by nuclear factor-kB (NF-kB)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
